埃塞俄比亚中部无症状HIV阳性和阴性个体中的患病率及根除治疗的疗效。

Prevalence of among asymptomatic HIV-positive and negative individuals in Central Ethiopia and efficacy of eradication therapy.

作者信息

Mesfun Million Getachew, Gliga Smaranda, Fuchs Andre, Orth Hans Martin, Schönfeld Andreas, Luedde Tom, Feldt Torsten

机构信息

Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Düsseldorf, Germany.

Hirsch Institute of Tropical Medicine, Asella, Ethiopia.

出版信息

IJID Reg. 2022 Jan 19;2:169-174. doi: 10.1016/j.ijregi.2022.01.007. eCollection 2022 Mar.

DOI:10.1016/j.ijregi.2022.01.007

PMID:35757079

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9216691/

Abstract

OBJECTIVES

is a widespread pathogen and major contributor to dyspeptic disease and gastric cancer. Although the interaction between HIV and infection is not well investigated, previous studies have suggested a decreased prevalence of and limited efficacy of eradication therapy in HIV-positive individuals. Therefore, the objectives of this study were to describe the prevalence of infection according to HIV status and analyze the efficacy of eradication therapy in Ethiopia.

METHODS

A prospective, randomized, interventional study was performed involving HIV-positive and negative participants presenting to the Asella Referral and Teaching Hospital in Central Ethiopia between March and June 2017. A stool antigen test was used as a screening tool for infection Randomly selected patients received triple eradication therapy.

RESULTS

The cumulative prevalence was 77.3% (392/507): 78.8% (241/306) among HIV-positive individuals versus 75.1% (151/201) among HIV-negative individuals ( = 0.386). Twenty-five HIV-positive and 26 HIV-negative -infected participants were randomized to receive standard triple therapy; three of them were lost to follow-up (one HIV-positive, two HIV-negative). The total eradication rate was 50.0%: 62.5% (15/24) among those HIV-negative versus 37.5% (9/24) among those HIV-positive [Au?1].

CONCLUSIONS

A high prevalence of was observed among HIV-positive and negative individuals in Central Ethiopia. The efficacy of eradication therapy was low, with a trend towards lower efficacy in HIV-infected individuals.

摘要

目的

幽门螺杆菌是一种广泛传播的病原体，是消化不良疾病和胃癌的主要致病因素。尽管人类免疫缺陷病毒（HIV）与幽门螺杆菌感染之间的相互作用尚未得到充分研究，但先前的研究表明，HIV阳性个体中幽门螺杆菌的感染率有所下降，且根除治疗的疗效有限。因此，本研究的目的是根据HIV感染状况描述幽门螺杆菌感染的患病率，并分析埃塞俄比亚根除治疗的疗效。

方法

2017年3月至6月，在埃塞俄比亚中部的阿塞拉转诊和教学医院对HIV阳性和阴性参与者进行了一项前瞻性、随机、干预性研究。粪便抗原检测被用作幽门螺杆菌感染的筛查工具。随机选择的患者接受三联根除治疗。

结果

幽门螺杆菌的累计患病率为77.3%（392/507）：HIV阳性个体中为78.8%（241/306），而HIV阴性个体中为75.1%（151/201）（P = 0.386）。25名HIV阳性和26名HIV阴性幽门螺杆菌感染参与者被随机分配接受标准三联疗法；其中3人失访（1名HIV阳性，2名HIV阴性）。总根除率为50.0%：HIV阴性者中为62.5%（15/24），而HIV阳性者中为37.5%（9/24）[AUC差值1]。